The Quantellect read.As of Nov 19, 2026, 12 active firms cover Teva Pharma Industries Ltd ADR: 12 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets are tightly clustered, $40.00 to $55.00, so the covering firms are broadly aligned. The average target of $45.92 sits 9% above the current $42.21. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 9 to 12 over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.61 next quarter toward $3.12 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS12 active firms
Buy
Strong Buy00%
Buy12100%
Neutral00%
Sell00%
Strong Sell00%
Based on 12 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$45.92
+8.8% upside
Average target across 12 active firms as of Nov 19, 2026 vs $42.21 current
Highest Target$55.00
Average Target$45.92
Lowest Target$40.00
Detailed analyst forecasts for TEVA
Showing 1–10 of 10 named analysts shown · 12 active firms in the rating projection
As of Nov 19, 2026, 12 of 12 active firms rate TEVA a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
TEVA EPS & revenue forecast
EPS · NEXT QUARTER
$0.61
Range $0.42 – $0.69 · 9 analysts
Next period, 9 analysts expect Teva Pharma Industries Ltd ADR to earn $0.61 a share (range $0.42 – $0.69), versus — a year earlier. Full-year consensus is $2.07, growing to $3.12 the year after.
REVENUE · NEXT QUARTER
$4.1B
Range $4.0B – $4.1B · 9 analysts · +2% YoY
Revenue is expected to reach $4.1B (range $4.0B – $4.1B), +2.2% year-over-year. Full-year consensus is $16.8B, rising to $17.3B next year.
Top analysts covering Teva Pharma Industries Ltd ADR
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on TEVA.
#1
Yatin Suneja
Guggenheim · Rank #84
Neutral
No targeton TEVA
Overall win rate
50%
+ Follow
#2
David Amsellem
Piper Sandler · Rank #124
Buy
$44.00+4.2% to target
Overall win rate
50%
+ Follow
#3
Jason Gerberry
B of A Securities · Rank #160
Buy
$48.00+13.7% to target
Overall win rate
47%
+ Follow
#4
CS
Chris Schott
JP Morgan · Rank #287
Buy
$50.00+18.5% to target
Overall win rate
41%
+ Follow
#5
GS
Glen Santangelo
Barclays
Buy
$47.00+11.3% to target
Coverage
—
+ Follow
TEVA stock forecast FAQ
What is TEVA's average 12-month price target?+
The 12 active firms with a live target average $45.92 for Teva Pharma Industries Ltd ADR over the next 12 months, ranging from a $55.00 high to a $40.00 low, as of Nov 19, 2026.
Is TEVA stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 12 active firms as of Nov 19, 2026, 12 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for TEVA?+
The Street-high target is $55.00 (TD Cowen), and the Street-low is $40.00 (Scotiabank). The average of all 12 active-firm targets is $45.92.
How many active Wall Street firms cover TEVA?+
12 active firms have a recognized rating on Teva Pharma Industries Ltd ADR as of Nov 19, 2026, and 12 active firms carry a live 12-month price target.
Who is the most accurate analyst covering TEVA?+
Among analysts who currently cover TEVA, Yatin Suneja of Guggenheim has the strongest overall Quantellect track record (Rank #84). Their current call is Neutral.
What is Teva Pharma Industries Ltd ADR's projected EPS for next quarter?+
The consensus estimate is $0.61 per share (range $0.42 – $0.69) across 9 analysts. Full-year EPS is projected at $2.07, rising to $3.12 the following year.
How much revenue is Teva Pharma Industries Ltd ADR expected to report next quarter?+
Consensus revenue is $4.1B (range $4.0B – $4.1B). Full-year revenue is projected at $16.8B, growing to $17.3B next year.
Have analysts been upgrading or downgrading TEVA lately?+
As of Nov 19, 2026, 12 of 12 active firms rate TEVA a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their TEVA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.